

World Journal of *Gastroenterology*

World J Gastroenterol 2024 April 14; 30(14): 1934-2067



EDITORIAL

- 1934 Topic highlight on texture and color enhancement imaging in gastrointestinal diseases
Toyoshima O, Nishizawa T, Hata K
- 1941 Immune checkpoint inhibitor-associated gastritis: Patterns and management
Lin J, Lin ZQ, Zheng SC, Chen Y
- 1949 Liver biopsy in the post-hepatitis C virus era in Japan
Ikura Y, Okubo T, Sakai Y
- 1958 Current status of liver transplantation for human immunodeficiency virus-infected patients in mainland China
Tang JX, Zhao D
- 1963 Bowel function and inflammation: Is motility the other side of the coin?
Panarese A

REVIEW

- 1968 Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions
Sun HJ, Jiao B, Wang Y, Zhang YH, Chen G, Wang ZX, Zhao H, Xie Q, Song XH

MINIREVIEWS

- 1982 Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Trinks J, Mascardi MF, Gadano A, Marciano S

ORIGINAL ARTICLE

Retrospective Study

- 1990 Characteristics of early gastric tumors with different differentiation and predictors of long-term outcomes after endoscopic submucosal dissection
Zhu HY, Wu J, Zhang YM, Li FL, Yang J, Qin B, Jiang J, Zhu N, Chen MY, Zou BC

Observational Study

- 2006 Preoperative albumin-bilirubin score and liver resection percentage determine postoperative liver regeneration after partial hepatectomy
Takahashi K, Gosho M, Miyazaki Y, Nakahashi H, Shimomura O, Furuya K, Doi M, Owada Y, Ogawa K, Ohara Y, Akashi Y, Enomoto T, Hashimoto S, Oda T

Basic Study

- 2018** *Fusobacterium nucleatum*-induced imbalance in microbiome-derived butyric acid levels promotes the occurrence and development of colorectal cancer
Wu QL, Fang XT, Wan XX, Ding QY, Zhang YJ, Ji L, Lou YL, Li X
- 2038** Comparative transcriptomic analysis reveals the molecular changes of acute pancreatitis in experimental models
Zheng P, Li XY, Yang XY, Wang H, Ding L, He C, Wan JH, Ke HJ, Lu NH, Li NS, Zhu Y

CASE REPORT

- 2059** Outcomes of endoscopic sclerotherapy for jejunal varices at the site of choledochojejunostomy (with video): Three case reports
Liu J, Wang P, Wang LM, Guo J, Zhong N

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Sandro Contini, MD, Former Associate Professor, Department of Surgical Sciences, University of Parma, Parma 43123, Italy. sandrocontini46@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*, Production Department Director: *Xiang Li*, Cover Editor: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

April 14, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Bowel function and inflammation: Is motility the other side of the coin?

Alba Panarese

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Banerjee A, United States; Poddighe D, Kazakhstan

Received: December 31, 2023

Peer-review started: December 31, 2023

First decision: January 10, 2024

Revised: January 23, 2024

Accepted: March 21, 2024

Article in press: March 21, 2024

Published online: April 14, 2024



Alba Panarese, Division of Gastroenterology and Digestive Endoscopy, Department of Medical Sciences, Central Hospital - Azienda Ospedaliera, Taranto 74123, Italy

Corresponding author: Alba Panarese, MD, Director, Division of Gastroenterology and Digestive Endoscopy, Department of Medical Sciences, Central Hospital - Azienda Ospedaliera, Francesco Bruno Street, 1, Taranto 74123, Italy. albapanarese@libero.it

Abstract

Digestion and intestinal absorption allow the body to sustain itself and are the emblematic functions of the bowel. On the flip side, functions also arise from its role as an interface with the environment. Indeed, the gut houses microorganisms, collectively known as the gut microbiota, which interact with the host, and is the site of complex immune activities. Its role in human pathology is complex and scientific evidence is progressively elucidating the functions of the gut, especially regarding the pathogenesis of chronic intestinal diseases and inflammatory conditions affecting various organs and systems. This editorial aims to highlight and relate the factors involved in the pathogenesis of intestinal and systemic inflammation.

Key Words: Motility; Inflammation; Pathogenesis; Vitamin D; Microbiota; Gut; Chronic intestinal pseudo-obstruction

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The pathophysiology and pathogenesis of inflammatory bowel diseases, functional bowel diseases and inflammatory diseases affecting other organs and systems is being defined. The gut is intended to be the site where inflammatory processes with systemic implications are triggered. A wide-ranging view is required to clarify these pathways with the aim of increasing differential diagnosis, early diagnosis, and treatment to improve prognosis of chronic bowel and systemic inflammation.

Citation: Panarese A. Bowel function and inflammation: Is motility the other side of the coin? *World J Gastroenterol* 2024; 30(14): 1963-1967

URL: <https://www.wjgnet.com/1007-9327/full/v30/i14/1963.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i14.1963>

INTRODUCTION

Bowel disease is a substantial and growing factor driving access to medical care, with notable economic and social impacts, especially in the context of chronic inflammatory diseases[1]. These diseases encompass not only inflammatory bowel disease (IBD), but also other intestinal inflammations, such as diverticulosis and functional disorders[2]. Additionally, chronic systemic and organ inflammation is also increasing, carrying both epidemiological and clinical implications[3]. Currently, the pathogenetic role of the gut in chronic systemic inflammation depends on the function of the gut barrier. This functionality is related to the composition of the gut microbiota and the activity of tight junctions, influenced by inflammatory factors, diet, hormones, and the enteric system[4]. The gut barrier disruption, the “leaky gut”, contributes to the development and progression of metabolic, ischemic, neoplastic, neurodegenerative and autoimmune systemic diseases with a substantial epidemiological impact[5-8].

The established role of gut microbiota/microbiome and intercellular junctions prompts a comprehensive exploration of all the factors influencing them. The rapidly accumulating volume of publications serves to enrich our understanding of biological processes and review data[9]. If environmental factors act unconditionally on all individuals, with variations across geographical area[2,5,9-11], among host factors, the genome is the most important. It determines intestinal nutrient absorption and availability, intrinsic intestinal motility, expression of structural proteins (including those of intercellular junctions), interaction with the gut microbiota, and immune response[3,7,8,12-14]. Gut and systemic inflammation, resulting from impaired gut immune activity, are primarily determined by genome[10,12-15]. The potential of intestinal inflammation to induce systemic inflammation may be attributed to the number of exogenous factors. These factors act over a very large surface, involving multiple types of cells and tissues[8-11,13,16]. The well-being of the human body depends on the homeostasis of the intestinal balance, which is unique in many respects. In the presence of favorable genetic characteristics exogenous factors have the potential to shift the immune response towards an inflammatory/autoimmune direction, carrying systemic implications[2-5,9,14,15,17].

RELEVANCE OF THE GENOME

Genome is the main determinant of gut biological processes for several reasons. First, the host genomics has an impact on the gut microbiota/microbiome[15-17]. Second, the genome determines the gut barrier, a dynamic structure that serves as a defense mechanism by shielding the intestinal structures and processes from external aggression[12,13,18]. The microbiota, located in the intestinal lumen, at the interface with the intestinal epithelium, interacts with the gut barrier[16,19]. Third, intestinal immune activity, protected by the gut barrier, also has characteristics conferred by the genome[3,13,14,16,20]. Therefore, exogenous factors, as well as the microbiota, interact with a genetically set immune response[21,22]. The expression of structural, enzymatic and functional proteins, including those involved in the gut barrier, immune response, digestive function and absorption, and neuromuscular components, depends on genetic characteristics[23,24].

The fact that family history is relevant in the onset of intestinal and systemic/organ diseases (inflammation, malabsorption, allergies and neuromuscular diseases) confirms the relevance of the genome, for genetic syndromes such as idiopathic chronic intestinal pseudo-obstruction (mutation in ACTG2, ERBB2-3, *etc.*) and for diseases in which immune and oxidative stress is a determining factor[25]. Obviously, phenotypic expression is influenced by exogenous factors that interfere with the immune activities of the lamina propria by crossing the gut barrier, as well as the genome[2,5,9,26]. In the presence of these factors, including the microbiota and the intestinal barrier, stromal cells, fibroblasts, endothelial cells, and inflammatory and immune cells, alter their interactions[2,4,5,11,13,16,27].

CENTRALITY OF MICROBIOTA, MOTILITY AND NUTRIENTS

Among the factors that act on intestinal biological processes, a phenotypic manifestation of the genome, the microbiota play a crucial role in both physiological and pathological conditions[2,4,5,7]. Various factors modify the microbiota and intestinal activities (the intestinal barrier, immune response, neuromuscular activity). Ultimately, these modifications can amplify or inhibit the inflammatory cascade[2,5,9,28-30]. Among the factors, vitamin D plays an important protective role because vitamin D signaling strengthens the gut barrier by upregulating the tight junctions of intestinal epithelial cells, and increasing the production of mucin and antibacterial peptides; downregulates dendritic cells activity; induces the differentiation and function of tolerogenic rather than pro-inflammatory T cells [increases the production of anti-inflammatory cytokines interleukin (IL)-4/IL-10 and decreases IL-17/IL-6/IL-2/interferon γ /tumor necrosis factor α][30]. Vitamin D/vitamin D receptor (VDR), by influencing both innate and adaptive immunity, plays a role in regulating the intestinal inflammation switch[30,31].

Scientific literature affirms the association between leaky gut and T cell dysfunction with the onset of conditions such as diabetes, cancers, depression and cardiovascular disease. Additionally, factors such obesity, diet, psychosocial stress, and early life stress are implicated in these associations[6,19,20]. Moreover, vitamin D signaling is related to type 2 diabetes, nonalcoholic fatty liver disease, multiple sclerosis and others autoimmune diseases, neurodegenerative diseases, allergies, cancers, IBDs, and chronic intestinal constipation[29,31-33]. Vitamin D deficiency may lead to gut dysbiosis and endotoxemia, potentially leading to systemic inflammation[22,30,31]. Essentially, vitamin D/VDR is involved in the pathogenesis of intestinal inflammation, with repercussions on systemic inflammation[30,31]. However, at the root of the pathogenetic sequence leading to diseases “related” to vitamin D deficiency there may be a defect in intestinal motility. Chronically reduced, whether idiopathic or secondary, intestinal motility can result in decreased absorption of vitamin D




Figure 1 Simplified model of gut homeostasis. Gut homeostasis depends on the balance between the human genome, intestinal barrier, microbiota, nutrients, hormones, exogenous factors, which interact with each other. Intestinal, systemic and organ inflammation results from impaired homeostasis. Gut homeostasis also depends on gut motility, which is determined by genes and other factors.

and other nutrients due to dysbiosis. Under favorable conditions, this scenario may lead to chronic intestinal and systemic inflammation[32]. By considering these premises, we can aim to prevent or treat diseases by modifying factors that reduce intestinal motility[25,34-41] (Figure 1).

CONCLUSION

Gut homeostasis depends on the balance between phenotype characteristics and exogenous factors, which collectively foster the stability of the microbiota. Clinical trials are required to validate the pathogenetic role of intestinal motility in impairing gut homeostasis consequently leading to inflammation with systemic involvement.

FOOTNOTES

Author contributions: Panarese A wrote and revised the manuscript.

Conflict-of-interest statement: The author reported no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Alba Panarese 0000-0002-6931-2171.

S-Editor: Wang JJ

L-Editor: A

P-Editor: Yuan YY

REFERENCES

- 1 **Agrawal M**, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. *United European Gastroenterol J* 2022; **10**: 1113-1120 [PMID: [36251359](#) DOI: [10.1002/ueg2.12317](#)]
- 2 **Sanmarco LM**, Chao CC, Wang YC, Kenison JE, Li Z, Rone JM, Rejano-Gordillo CM, Polonio CM, Gutierrez-Vazquez C, Piester G, Plasencia A, Li L, Giovannoni F, Lee HG, Faust Akl C, Wheeler MA, Mascanfroni I, Jaronen M, Alsuwailm M, Hewson P, Yeste A, Andersen BM, Franks DG, Huang CJ, Ekwudo M, Tjon EC, Rothhammer V, Takenaka M, de Lima KA, Linnerbauer M, Guo L, Covacu R, Queva H, Fonseca-Castro PH, Bladi MA, Cox LM, Hodgetts KJ, Hahn ME, Mildner A, Korzenik J, Hauser R, Snapper SB, Quintana FJ. Identification of environmental factors that promote intestinal inflammation. *Nature* 2022; **611**: 801-809 [PMID: [36266581](#) DOI: [10.1038/s41586-022-05308-6](#)]
- 3 **Furman D**, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM. Chronic inflammation in the etiology of disease across the life span. *Nat Med* 2019; **25**: 1822-1832 [PMID: [31806905](#) DOI: [10.1038/s41591-019-0675-0](#)]
- 4 **Di Vincenzo F**, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. *Intern Emerg Med* 2024; **19**: 275-293 [PMID: [37505311](#) DOI: [10.1007/s11739-023-03374-w](#)]
- 5 **Malesza IJ**, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, Bartkowiak-Wieczorek J, Mądry E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. *Cells* 2021; **10** [PMID: [34831387](#) DOI: [10.3390/cells10113164](#)]
- 6 **Martel J**, Chang SH, Ko YF, Hwang TL, Young JD, Ojcius DM. Gut barrier disruption and chronic disease. *Trends Endocrinol Metab* 2022; **33**: 247-265 [PMID: [35151560](#) DOI: [10.1016/j.tem.2022.01.002](#)]
- 7 **Mou Y**, Du Y, Zhou L, Yue J, Hu X, Liu Y, Chen S, Lin X, Zhang G, Xiao H, Dong B. Gut Microbiota Interact With the Brain Through Systemic Chronic Inflammation: Implications on Neuroinflammation, Neurodegeneration, and Aging. *Front Immunol* 2022; **13**: 796288 [PMID: [35464431](#) DOI: [10.3389/fimmu.2022.796288](#)]
- 8 **Liu X**, Liu Y, Liu J, Zhang H, Shan C, Guo Y, Gong X, Cui M, Li X, Tang M. Correlation between the gut microbiome and neurodegenerative diseases: a review of metagenomics evidence. *Neural Regen Res* 2024; **19**: 833-845 [PMID: [37843219](#) DOI: [10.4103/1673-5374.382223](#)]
- 9 **Usuda H**, Okamoto T, Wada K. Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier. *Int J Mol Sci* 2021; **22** [PMID: [34299233](#) DOI: [10.3390/ijms22147613](#)]
- 10 **Chang CS**, Kao CY. Current understanding of the gut microbiota shaping mechanisms. *J Biomed Sci* 2019; **26**: 59 [PMID: [31434568](#) DOI: [10.1186/s12929-019-0554-5](#)]
- 11 **Andersen-Civil AIS**, Arora P, Williams AR. Regulation of Enteric Infection and Immunity by Dietary Proanthocyanidins. *Front Immunol* 2021; **12**: 637603 [PMID: [33717185](#) DOI: [10.3389/fimmu.2021.637603](#)]
- 12 **Wibbe N**, Ebnet K. Cell Adhesion at the Tight Junctions: New Aspects and New Functions. *Cells* 2023; **12** [PMID: [38067129](#) DOI: [10.3390/cells12232701](#)]
- 13 **Spalinger MR**, Sayoc-Becerra A, Santos AN, Shawki A, Canale V, Krishnan M, Niechcial A, Obialo N, Scharl M, Li J, Nair MG, McCole DF. PTPN2 Regulates Interactions Between Macrophages and Intestinal Epithelial Cells to Promote Intestinal Barrier Function. *Gastroenterology* 2020; **159**: 1763-1777.e14 [PMID: [32652144](#) DOI: [10.1053/j.gastro.2020.07.004](#)]
- 14 **Kline EM**, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. *Mov Disord* 2021; **36**: 25-36 [PMID: [33314312](#) DOI: [10.1002/mds.28411](#)]
- 15 **Qin Y**, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta L, Brożyńska M, Zhu Q, Tripathi A, Vázquez-Baeza Y, Loomba R, Cheng S, Jain M, Niiranen T, Lahti L, Knight R, Salomaa V, Inouye M, Méric G. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. *Nat Genet* 2022; **54**: 134-142 [PMID: [35115689](#) DOI: [10.1038/s41588-021-00991-z](#)]
- 16 **Kayama H**, Okumura R, Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. *Annu Rev Immunol* 2020; **38**: 23-48 [PMID: [32340570](#) DOI: [10.1146/annurev-immunol-070119-115104](#)]
- 17 **Kolde R**, Franzosa EA, Rahnavard G, Hall AB, Vlamakis H, Stevens C, Daly MJ, Xavier RJ, Huttenhower C. Host genetic variation and its microbiome interactions within the Human Microbiome Project. *Genome Med* 2018; **10**: 6 [PMID: [29378630](#) DOI: [10.1186/s13073-018-0515-8](#)]
- 18 **Yao Y**, Kim G, Shafer S, Chen Z, Kubo S, Ji Y, Luo J, Yang W, Perner SP, Kanellopoulou C, Park AY, Jiang P, Li J, Baris S, Aydinler EK, Ertem D, Mulder DJ, Warner N, Griffiths AM, Topf-Olivestone C, Kori M, Werner L, Ouahed J, Field M, Liu C, Schwarz B, Bosio CM, Ganesan S, Song J, Urlaub H, Oellerich T, Malaker SA, Zheng L, Bertozzi CR, Zhang Y, Matthews H, Montgomery W, Shih HY, Jiang J, Jones M, Baras A, Shuldiner A, Gonzaga-Jauregui C, Snapper SB, Muise AM, Shouval DS, Ozen A, Pan KT, Wu C, Lenardo MJ. Mucus sialylation determines intestinal host-commensal homeostasis. *Cell* 2022; **185**: 1172-1188.e28 [PMID: [35303419](#) DOI: [10.1016/j.cell.2022.02.013](#)]
- 19 **Di Tommaso N**, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. *Int J Environ Res Public Health* 2021; **18** [PMID: [34886561](#) DOI: [10.3390/ijerph182312836](#)]
- 20 **Montgomery TL**, Künstner A, Kennedy JJ, Fang Q, Asarian L, Culp-Hill R, D'Alessandro A, Teuscher C, Busch H, Kremontsov DN. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity. *Proc Natl Acad Sci U S A* 2020; **117**: 27516-27527 [PMID: [33077601](#) DOI: [10.1073/pnas.2002817117](#)]
- 21 **Kopp EB**, Agaronyan K, Licona-Limón I, Nish SA, Medzhitov R. Modes of type 2 immune response initiation. *Immunity* 2023; **56**: 687-694 [PMID: [37044059](#) DOI: [10.1016/j.immuni.2023.03.015](#)]
- 22 **Geuking MB**, Burkhard R. Microbial modulation of intestinal T helper cell responses and implications for disease and therapy. *Mucosal Immunol* 2020; **13**: 855-866 [PMID: [32792666](#) DOI: [10.1038/s41385-020-00335-w](#)]
- 23 **Li X**, Li W, Zeng M, Zheng R, Li M. Network-based methods for predicting essential genes or proteins: a survey. *Brief Bioinform* 2020; **21**: 566-583 [PMID: [30776072](#) DOI: [10.1093/bib/bbz017](#)]
- 24 **Poddighe D**, Capittini C. The Role of HLA in the Association between IgA Deficiency and Celiac Disease. *Dis Markers* 2021; **2021**: 8632861 [PMID: [35186163](#) DOI: [10.1155/2021/8632861](#)]
- 25 **Stavely R**, Ott LC, Rashidi N, Sakkal S, Nurgali K. The Oxidative Stress and Nervous Distress Connection in Gastrointestinal Disorders. *Biomolecules* 2023; **13** [PMID: [38002268](#) DOI: [10.3390/biom13111586](#)]
- 26 **Guo T**, Li X. Machine learning for predicting phenotype from genotype and environment. *Curr Opin Biotechnol* 2023; **79**: 102853 [PMID: [36463837](#) DOI: [10.1016/j.copbio.2022.102853](#)]

- 27 **Nolan LS**, Rimer JM, Good M. The Role of Human Milk Oligosaccharides and Probiotics on the Neonatal Microbiome and Risk of Necrotizing Enterocolitis: A Narrative Review. *Nutrients* 2020; **12** [PMID: 33036184 DOI: 10.3390/nu12103052]
- 28 **Wang J**, Thingholm LB, Skiecevičienė J, Rausch P, Kummén M, Hov JR, Degenhardt F, Heinsen FA, Rühlemann MC, Szymczak S, Holm K, Esko T, Sun J, Pricop-Jeckstadt M, Al-Dury S, Bohov P, Bethune J, Sommer F, Ellinghaus D, Berge RK, Hübenthal M, Koch M, Schwarz K, Rimbach G, Hübbe P, Pan WH, Sheibani-Tezerji R, Häslér R, Rosenstiel P, D'Amato M, Cloppenburg-Schmidt K, Künzel S, Laudes M, Marschall HU, Lieb W, Nöthlings U, Karlsen TH, Baines JF, Franke A. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. *Nat Genet* 2016; **48**: 1396-1406 [PMID: 27723756 DOI: 10.1038/ng.3695]
- 29 **Vernia F**, Valvano M, Longo S, Cesaro N, Viscido A, Latella G. Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications. *Nutrients* 2022; **14** [PMID: 35057450 DOI: 10.3390/nu14020269]
- 30 **Sassi F**, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. *Nutrients* 2018; **10** [PMID: 30400332 DOI: 10.3390/nu10111656]
- 31 **L Bishop E**, Ismailova A, Dimeloe S, Hewison M, White JH. Vitamin D and Immune Regulation: Antibacterial, Antiviral, Anti-Inflammatory. *JBM R Plus* 2021; **5**: e10405 [PMID: 32904944 DOI: 10.1002/jbm4.10405]
- 32 **Panarese A**, Pesce F, Porcelli P, Riezzo G, Iacovazzi PA, Leone CM, De Carne M, Rinaldi CM, Shahini E. Chronic functional constipation is strongly linked to vitamin D deficiency. *World J Gastroenterol* 2019; **25**: 1729-1740 [PMID: 31011257 DOI: 10.3748/wjg.v25.i14.1729]
- 33 **Khatoun S**, Kalam N, Rashid S, Bano G. Effects of gut microbiota on neurodegenerative diseases. *Front Aging Neurosci* 2023; **15**: 1145241 [PMID: 37323141 DOI: 10.3389/fnagi.2023.1145241]
- 34 **Giambra V**, Pagliari D, Rio P, Totti B, Di Nunzio C, Bosi A, Giaroni C, Gasbarrini A, Gambassi G, Cianci R. Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity. *Cells* 2023; **12** [PMID: 37998389 DOI: 10.3390/cells12222654]
- 35 **Katsirma Z**, Dimidi E, Rodriguez-Mateos A, Whelan K. Fruits and their impact on the gut microbiota, gut motility and constipation. *Food Funct* 2021; **12**: 8850-8866 [PMID: 34505614 DOI: 10.1039/d1fo01125a]
- 36 **Ding N**, Zhang X, Zhang XD, Jing J, Liu SS, Mu YP, Peng LL, Yan YJ, Xiao GM, Bi XY, Chen H, Li FH, Yao B, Zhao AZ. Impairment of spermatogenesis and sperm motility by the high-fat diet-induced dysbiosis of gut microbes. *Gut* 2020; **69**: 1608-1619 [PMID: 31900292 DOI: 10.1136/gutjnl-2019-319127]
- 37 **Fournier N**, Fabre A. Smooth muscle motility disorder phenotypes: A systematic review of cases associated with seven pathogenic genes (ACTG2, MYH11, FLNA, MYLK, RAD21, MYL9 and LMOD1). *Intractable Rare Dis Res* 2022; **11**: 113-119 [PMID: 36200034 DOI: 10.5582/irdr.2022.01060]
- 38 **Zhernakova DV**, Wang D, Liu L, Andreu-Sánchez S, Zhang Y, Ruiz-Moreno AJ, Peng H, Plomp N, Del Castillo-Izquierdo Á, Gacesa R, Lopera-Maya EA, Temba GS, Kullaya VI, van Leeuwen SS; Lifelines Cohort Study, Xavier RJ, de Mast Q, Joosten LAB, Riksen NP, Rutten JHW, Netea MG, Sanna S, Wijmenga C, Weersma RK, Zhernakova A, Harmsen HJM, Fu J. Host genetic regulation of human gut microbial structural variation. *Nature* 2024; **625**: 813-821 [PMID: 38172637 DOI: 10.1038/s41586-023-06893-w]
- 39 **Wang S**, Hou H, Tang Y, Zhang S, Wang G, Guo Z, Zhu L, Wu J. An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes. *Neural Regen Res* 2023; **18**: 2357-2364 [PMID: 37282453 DOI: 10.4103/1673-5374.371400]
- 40 **Sarfo BO**, Kopdag H, Pott MC, Stiedenroth L, Nahrstedt U, Schäfer H, von Wichert G. Postinfectious T-lymphocytic enteric leiomyositis as a rare cause of chronic intestinal pseudoobstruction. *Z Gastroenterol* 2021; **59**: 326-330 [PMID: 33845499 DOI: 10.1055/a-1310-4500]
- 41 **Radocchia G**, Neroni B, Marazzato M, Capuzzo E, Zuccari S, Pantanella F, Zenzeri L, Evangelisti M, Vassallo F, Parisi P, Di Nardo G, Schippa S. Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota? *Microorganisms* 2021; **9** [PMID: 34946150 DOI: 10.3390/microorganisms9122549]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

